Why raise a community round from retail investors? Has AJNA Biosciences received $$$$$ from traditional VCs and can you share who they are?

To date, AJNA has raised $25 million from accredited investors and institutional investors, including $10.1 million from a private round and $15 million from British American Tobacco who invested in our lead drug AJA001. Included in the private round is PhiFund Ventures. We are raising a community round to give our employees, friends, family, and plant medicine supporters who are not accredited investors the chance to invest in our mission and join us on the journey to become a leading botani...

Hi, great presentation. I am impressed and quite interested. I want to echo the question posed below - I'm a huge fan of Wefunder and have invested in many projects here, but I'm curious how you've done with other types of funding, given your strong background and the power of...

Hi Alan, the off-platform investments have come from a private investment round whereby accredited investors in our network invested in AJNA on the same terms being offered to the general public via this community round on Wefunder. On the science end- we have a robust botanical drug development program and we operate a state-of-the-art 13,500 sq. ft. lab with clearance to process United States Drug Enforcement Agency (DEA) Schedule 1 substances - which is quite rare among biotech companies. ...

Love the enhanced 20 year patent lifetimes on these drugs, the support of BAT ($70B market cap) as a two time funder of yours -- both with Charlotte's Web ($60M for 20%) and in DeFloria ($10M for 20% interest in AJA001), and reduced risk of trial complications as people have b...

Hi Jason, We appreciate your patience with our response. You asked some good and in-depth questions, and we want to get you the best answers. To answers your questions: "Does DeFloria have additional funds not included in your balance sheet?" Yes. "Looking at your next raise in 12-18 months, what trial results do you anticipate having at that point?" For AJA 001 - According to our Milestones Chart, once we enter Phase 2 (Open Label Entrance + FDA NOL + Pediatric Entrance) that will position u...

Can you share your thoughts on how often you will update us on how things are progressing with your goals and business plan? Secondly, do you intend to file the annual report with the SEC? Thanks for your feedback.

Hi Eric, thank you for your question! Please follow our campaign. We will be updating all interested parties 2 x week. Following ensures you receive every update we post. We send out periodic updates to our investors, on a semi-annual basis, as pertinent and impactful milestones are achieved across AJNA. We file any necessary forms with the SEC.

You're talking about partnerships and IP Licensing, who are your partners and your customers? Can you give us a couple names? Thank you!

Hi again Lea, our current partners are BAT and Charlotte's Web. Our customer base are patients within our first two indications (GAD & ASD), and/or pharmaceutical companies buying our drugs. Once FDA approved, our products will be available for all and support anyone effected by their conditions, our communities, and those who believe in natural medicine. Thanks again

AJNA BioSciences Updates, Team, and Funding Progress | Wefunder, Home of the Community Round

Led by industry pioneers who filed first-ever cannabis patent & brought a cannabidiol company to IPO

Powered by world-class scientists from Harvard Medical, Johns Hopkins, and NYU

Leading a new frontier in the $678B pharmaceutical industry

Phase 1 trial for Psilocybin-based antidepressant drug planned for early 2025

Phase 2 trial for CBD-based Autism Spectrum Disorder drug planned for late 2024

2 botanical drug candidates in pipeline for FDA approval with additional drugs in discovery

Green process with IP for solventless extraction methods

AJNA BioSciences

Transforming the $678B pharma industry with plant medicine, leading with psilocybin and cannabinoids

$2,119,232

AJNA BioSciences

Quick facts

Investor memo sources

Team profiles

Featured investor profiles

$2,119,232

Ask